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Abstract 
Mixed  acinar-endocrine  carcinomas
(MAEC) are rare tumors of the pancreas. We
present  the  case  of  a  patient  with  peri-
ampullary tumor that presented with painless
jaundice and after investigation was found to
have  MAEC.  He  underwent  pancreaticoduo-
dunectomy with tumor free margins and nega-
tive lymph nodes. The patient presented with
local recurrence and liver metastasis after 1
year  and  is  on  chemotherapy  with  stable
lesions 30 months after the diagnosis. 
Introduction
Pancreatic  tumors  are  rare  and  constitute
less than 1% of all neoplasms. Adenocarci  nomas
represent more than 75% of pancreatic cancer,
neuroendocrine carcinomas are 7% and acinar
cell carcinomas (ACC) are 1%.1 Mixed endo  -
crine-exocrine tumors of the pancreas are also
very  rare.  The  World  Health  Organization
(WHO) classified these tumors as either mixed
ductal-endocrine  carcinomas  that  are  part  of
the ductal carcinomas, and should have more
than 30 % endocrine component, or mixed aci-
nar-endocrine carcinomas (MAEC) that are part
of  the  ACC  and  should  have  at  least  30%
endocrine  component.2 Another  classification
for  mixed  tumors  from  the  Atlas  of  Tumor
pathology  (fourth  series)  dictates  that  each
component has to compose at least 25% of the
total cells.3 We present a case of a 52 years old
male patient who presented with MAEC with a
review of the literature.
Case Report
A 52 year-old male patient presented to our
institution  with  epigastric  pain,  fatigue  and
jaundice.  Computed  tomography  (CT)  scan
revealed a dilated commom bile duct (CBD).
Endoscopic retrograde cholangiopancreatogra-
phy  revealed  a  mass  in  the  vicinity  of  the
ampulla of Vater obstructing the lumen. Fine
needle aspiration (FNA) revealed a neuroen-
docrine tumor. Past medical history was posi-
tive for atrial fibrillation and the patient was a
45 pack-year smoker.
His laboratory studies were as follow: total
bilirubin  8.8  mg/dL  (normal  range  0-1.2),  7
mg/dL  direct  bilirubin  (normal  range  0-0.3),
SGOT 56 IU/L (normal range 0-50), SGPT 75
IU/L (normal range 0-65), ʳ-GT 220 IU/L (nor-
mal range 10-50), lipase level 119 U/L (normal
range  13-60)  and  alkaline  phosphatase  332
IU/L (normal range 35-120). 
A  standard  pancreaticoduodunectomy  was
performed  and  pathology  revealed  an
ampullary  tumor  measuring  1.5ﾥ1.2ﾥ1  cm
compressing but not obstructing the opening.
Microscopic examination of the mass showed
that the tumor was composed of two cell types:
75%  of  cells  with  endocrine  differentiation
(islet cells) and the other 25% with exocrine
features (acinar). The endocrine component
had relatively well differentiated areas as well
as moderately differentiated areas with brisk
mitotic activity (up to 5 per single HPF). The
exocrine component consisted of well differen-
tiated cells arranged in acini (Figure 1). The
tumor originated in the ampulla and eroded
the duodenal mucosa but didn’t infiltrate the
ampullary lumen. The surgical margins were
free of tumor. Immunohistochemistry was dif-
fusely positive for chromogranin and the aci-
nar  portion  was  focally  positive.  All  lymph
nodes were negative for metastasis.
Follow up CT scans at 4 months post surgery
did not show evidence of tumor recurrence.
One year after, he presented to the emer-
gency room with severe epigastric pain radiat-
ing to the back. CT scan showed local recur-
rence  in  addition  to  liver  metastasis  and
paraaortic soft tissue mass. FNA of both mass-
es confirmed a high grade tumor similar to the
original tumor resected. The masses were pos-
itive for chromagranin and synoptphysin.
The  patient  was  started  on  cisplatin  (50
mg/m2)  and  Camtothecin  (180  mg/m2).  This
treatment was planned to be given every two
weeks. Before the forth cycle, serotonin level
and  chromagranin  A  level  were  392  ng/mL
(normal  151-186)  and  2380  (normal  <100)
respectively.  CT  scan  performed  after
chemotherapy and showed a reduction in the
liver lesions. Another 4 cycles were given and a
repeat CT scan revealed a decrease in the size
of the liver lesions. The new serotonin level
was 205 and the chromagranin A level was 391.
After  the  7th cycle,  CT  scan  showed  a  mild
increase  in  the  liver  nodules.  A  different
chemotherapy protocol was initiated and con-
sisted of 2 cycles of 1250 mg/m2of Gemcitabine
followed after 1 hour by 50 mg/m2 of cisplatin.
The patient is now on same protocol but oxali-
patin (100 mg/m2) instead of cisplatin because
of adverse drug reaction.   
Recent  CT  scan  of  abdomen  and  pelvis
showed progressive hepatic disease with sta-
ble extrahepatic pancreatic – bed lesion. PET
CT scan with Gallium (68) didn’t reveal any
activity  in  both  hepatic  and  extrahepatic
lesions (Figure 2).
Discussion
Pancreatic tumors can originate from aci-
nar, ductal or endocrine cell types.1 However it
has been reported that pancreatic neoplasms
can exhibit more than one line of cellular dif-
ferentiation.2 Mixed exocrine-endocrine neo-
plasms of the pancreas are rare tumors, char-
acterized  by  the  association  of  an  exocrine-
ductal or acinar component and a significant
endocrine  component  that  comprise  at  least
one-third to one-half of the total tumor tissue
(Tables 1 and 2).1,4
Cubilla et al reported in his large series the
incidence  of  MAEC  to  be  0.2%.5 MAEC  can
present in 3 different combinations: a tumor
with  separate  acinar  and  endocrine  regions
identifiable  by  light  microscopy  (Collision
tumor),  a  mixture  of  endocrine  and  acinar
cells (intermingled tumor) and a tumor with
uniform cell population by light microscopy but
with amphicirne features immunohistochemi-
cally.1,6 The histogenesis of MAEC is still con-
troversial;  the  co-existence  of  exocrine  and
endocrine  elements  in  these  tumors  can  be
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attributed to their common embryologic origin
(Tables  1  and  2).7,8 Although  the  biologic
aggressiveness  of  MAEC  is  still  uncertain
because of the small number of cases, Klimstra
et al. suggested that the behavior of MAEC may
be similar to that of acinar cell carcinoma.6
It  is  not  known  whether  mixed  acinar-
endocrine carcinomas are simply an acinar cell
carcinoma  with  an  increased  number  of
endocrine cells or is developmentally distinct
from acinar cell carcinoma. Koboayashi et al.
reviewed  21  cases  of  mixed  exocrine-
endocrine  carcinoma  (Table  1  and  2).9 The
tumor can develop in any part of the pancreas,
but they were relatively common in pancreatic
head. Metastasis was observed in 6 cases with
a mean survival time of 20.6 months. He con-
cluded that MEAC have a similar behavior of
malignancy to that of acinar cell carcinoma.
Our patient relapsed 18 months after the sur-
gery and the main site of relapse was locore-
gional with liver metastasis. He responded par-
tially to chemotherapy and he is still alive 30
months  after  diagnosis.  To  the  best  of  our
knowledge,  no  specific  chemotherapeutic
agents targeting MEAC were discussed in liter-
ature. The chemotherapy regimen given to our
patient  was  based  on  the  AUB  tumor  board
Case Report
Figure 2. Computed tomography scan of
the  abdomen  showing  the  recurrent
lesions.  (1)  The  liver  lesions  that  were
detected on computed  tomography  scan.
(2) The recurrent mass in the left para-aor-
tic  region.  (3)  Latest  image  of  the  liver
lesions that show regression in size after
the treatment in comparison to 1st image.
(4) Regression of the mass in the primary
site of the neoplasm.
Table 1. Immunohistochemistry staining in reported cases of mixed acinar-endocrine
carcinomas of the pancreas.
Author Immunohistochemistry 
Ohike4 + ve Synaptophysin, CGA, trypsin
Virlos7 + ve lysozyme, ʱ-1 antitrypsin, chromogranin
Kobayashi9 –ve insulin, glucagon, somatostatin, amylase, serotonin, CEA, neuron-specific enolase, MUC1
+ve chromogranin-A, synaptophysin , alpha-amylase, lipase, ʱ-fetoprotein
Kyriazi11 +ve chromogranin, synaptophysin, NSE, C56, CK7, ʱ-antitrypsin
+ve trypsin, chromogranin A, CA19-9
Imaoka12 +ve trypsin, chymotrypsin, chromogranin A, synaptophysin
Chung13 +ve trypsin, Synaptophysin
Frank14 -ve Somatostatin-receptor scintigraphy with octreotide (Octreoscan)
Ja-cho15 +ve amylase, chromagranin, neuron specific enolase, glucagon, 
somatostatin, gastrin
Kusafuka16 –ve CD56,  insulin, and other hormones
Our case +ve chromogranin, synoptphysin
CGA, chromogranin A; CEA, Carcinoembryonic antigen; NSE, neuron-specific enolase; MUC1, Mucin 1, cell surface associated.
Figure  1.  Histological  sections  of  the  resected  mass.  (1)  Low  magnification  showing
tumor extending into duodenal mucosa. (H&E, 20x). (2) Higher magnification showing
the acinar exocrine component of the tumor (left) and endocrine component (right).
(H&E, 100x). (3) The exocrine component consists of well differentiated cells arranged
in acini. (H&E, 400x). (4) Portion of the endocrine component showing nests of tumor
cells with chromogranin A positivity (400x).[page 46] [Rare Tumors 2011; 3:e15]
decision, which was in turn extrapolated from
the  treatment  of  Acinar  cell  carcinoma  and
endocrine  carcinoma  of  the  pancreas  since
they share similar components.
Hange A et al., reported recently 96% sensi-
tivity for (68) Ga-DOTA-TATE PET compared to
56%  for  (18)  F-DOPA  PET  for  detection    of
metastasis in neuroendocrine tumor, but no
data were reported in mixed acinar-endocrine
tumor.10 Our patient did not show any activity
either in the liver or at the site of locoregional
disease recurrence with (68) Gallium DOTTA-
TATE  PET  CT  scan  which  may  reflect  the
absence  of  somatostatin  receptors  in  such
tumors. Since our case has no secretory activ-
ity with negative (68) Ga PET CT Scan, 18F-
DOPA PET CT Scan will not be of help.  
In conclusion, MEAC is a very rare condition
with relatively poor prognosis. Due to the small
number of cases reported, there are still many
controversies  regarding  the  treatment  of
choice  for  those  tumors.  Therefore,  surgery
should  continue  to  be  the  gold  standard  of
their treatment, since it has been the one to
demonstrate  satisfactory  long-term  survival
results (Table 1 and 2).11
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Case Report
Table 2. Reported cases of mixed acinar-endocrine carcinomas of the pancreas in the literature.
Author N of case Presentation Age/Sex Location and size Treatment Survival
Ohike3 6 Abdomial pain 49-65,F:M 2:1 Mean size: 8.2 cm  Resection NA
Klimstra6 5 Abdominal pain 81 M Tail, 3 cm Resection Alive
Incidental mass 70 M Multi 4×10 cm Resection Dead
Hematemesis 64 F Head, 10 cm Biopsy and bypass Dead
Incidental mass 48 F Tail, 11 cm Resection Dead
Abdominal pain  70 F Head, 10 cm Biopsy and bypass Alive
Virlos7 1 Pruritus, weight loss 33 M Head, 3.5 cm  PPPD Alive
Kobayashi9 1 Asymptomatic  75 M Tail Resection Alive
Kyriazi11 1 Polyarthralgia  74 M Head, 9×6 cm Whipple’s procedure  NA
Imaoka12 1 Lymphadenopathy  80 M  Head, 4 cm  Whipple procedure  NA
Chung13 1 Watery diarrhea  59 F Tail, 8×2.5 cm  PPPD Na
Frank14 1 Abdominal pain 61 M Head & body Whipple procedure  Dead
Ja-cho15 1 Jaundice  52 F Uncinate process Whipple procedure Alive
Kusafuka16 1 Abdominal pain 56 F Stomach Resection NA
Momcur17 1 Back pain  78 M Duodenum , 2.3 cm No surgery Dead
Ulich18 1 Asymptomatic  30 F Head  5.8 cm  Whipple procedure  Alive
Nishii19 1 Abdominal pain 60 F Head PPPD NA
Our case 1 Abdominal pain 52 M Head Whipple procedure NA
PPPD, pylorus preserving pancreaticoduodunectomy, NA, not available